Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,460
Open 25.26
Bid (Size) 25.47 (3)
Ask (Size) 25.49 (4)
Prev. Close 25.26
Today's Range 25.26 - 25.26
52wk Range 25.23 - 40.37
Shares Outstanding 5,606,688,356
Dividend Yield 6.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
Exposures Product Safety
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire

Performance

YTD
-15.04%
-15.04%
1 Month
-8.45%
-8.45%
3 Month
-8.05%
-8.05%
6 Month
-18.93%
-18.93%
1 Year
-34.61%
-34.61%

More News

Read More
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Creative Biolabs: The Way ADCs Are Made Has Changed
Via Get News
US Stock: Pfizer
Via Talk Markets
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Pfizer Declares Second-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
3 Defensive Stocks To Protect Your Portfolio In 2024
Via Talk Markets
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
Exposures COVID-19
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
Via InvestorPlace
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Capturing Consumer Spending on Health Care with XLV
Via News Direct
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
Via The Motley Fool
If You'd Invested $1,000 in Pfizer 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
Via InvestorPlace
3 No-Brainer Stocks to Buy With $100 Right Now
Via The Motley Fool
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.